THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this offering were $18 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by Opexa. Opexa has also granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock to cover over-allotments, if any. Opexa intends to use the net proceeds from the offering to fund further clinical development of Tcelna in an ongoing Phase IIb clinical study of patients with Secondary Progressive MS as well as the expenses of its operations during such development and for general corporate purposes. Opexa may also use a portion of the net proceeds to repay all or a portion of its outstanding convertible secured promissory notes. Aegis Capital Corp. acted as sole book-running manager for the offering. A registration statement relating to these securities was declared effective … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the company will report financial results for the three months ended June 30, 2013, before the opening of trading on Wednesday, August 14th. The company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 8 A.M. Eastern Time on Wednesday, August 14th. Conference Call and Webcast Details To listen to the conference call, dial in approximately ten minutes before the scheduled 8 AM time to (253) 237-1170 or toll free at (877) 372-0867. Please reference conference ID #31008302 while dialing into the call. A live webcast of the call can also be accessed via the webcast link on our website (www.opexatherapeutics.com) or by going to the following URL: http://investor.shareholder.com/media/eventdetail.cfm?eventid=133472&CompanyID=OPXA&e=1&mediaKey=52AF10A2390CE08BC8D2847172A3B20C There will be a brief Question & Answer session following management commentary. Shareholders and interested parties are highly encouraged to submit questions in advance by e-mail addressed to kradhakrishnan@opexatherapeutics.com. About Opexa Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, … Continue reading →

SAVANNAH, Ga. A federal judge Monday threw out race discrimination claims by a former Savannah restaurant manager whose lawsuit against Paula Deen has already cost the celebrity cook a valuable chunk of her culinary empire. Lisa Jackson sued Ms. Deen and her brother, Bubba Hiers, last year saying she suffered from sexual harassment and racially offensive talk and employment practices that were unfair to black workers during her five years as a manager of Uncle Bubbas Seafood and Oyster House. Ms. Deen is co-owner of the restaurant, which is primarily run by her brother. But claims of race discrimination by Ms. Jackson, who is white, were gutted in the 20-page opinion by U.S. District Court Judge William T. Moore Jr. The judge agreed with lawyers for Ms. Deen and Mr. Hiers that Ms. Jackson has no standing to sue her former employers for what she claims was poor treatment of black workers, regardless of her claims that she was offended and placed under additional stress. Ms. Jackson, at best, is an accidental victim of the alleged racial discrimination, Mr. Moore said in his ruling. There are no allegations that defendant Hierss racially offensive comments were either directed toward plaintiff or … Continue reading →

SARATOGA, Calif. & CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF) and Gencia Corporation today announced a collaboration to advance myelin repair therapeutic development for Multiple Sclerosis (MS). Through its unique Accelerated Research Collaboration (ARC) model, the Myelin Repair Foundation will partner with Gencia Corporation to assess the myelin regenerating capabilities of the companys proprietary therapeutic compounds for MS. We are thrilled to be working with Gencia to examine new ways to treat MS. As a non-profit organization, we seek to partner with innovative companies doing exciting MS research in myelin repair. Through this unique partnership, Gencia Corporation will work closely with researchers at the Myelin Repair Foundations Translational Medicine Center, a laboratory facility dedicated to the evaluation of promising multiple sclerosis candidates for myelin repair. Led by MRF personnel with extensive biopharma experience moving therapeutic compounds into the clinic, the MRF Translational Medicine Center investigates and advances promising myelin repair drug targets toward commercialization. The Myelin Repair Foundations patient-centric, collaborative approach to develop the next generation of MS therapeutics makes them an ideal partner for us to bring new treatments to the clinic, said President and CEO Allen Cunningham from Gencia Corporation. We are excited to work side by side … Continue reading →

Ms Roberts, a New Zealander living in Brighton, East Sussex, appeared on the television show ahead of a documentary, You're Killing My Son:The Mum Who Went On The Run, which will be shown on Channel 4 tonight. Following the ruling, Ms Roberts and her son disappeared but were found four days later. Ms Roberts told Daybreak she still believed that there were alternative treatments for her son which would not have such a damaging effect on him. She said: "I think his co-ordination and his spirit have been crushed. He's very much feeling pretty rubbish." She said that although doctors have told her Neon is doing well, she found it a "strange description". She said: "He's hiding away from the world, always building dens around himself. "The treatment itself is a carcinogenic immuno-suppressor for salt on the body. There are a multitude of other treatments out there. "I have mentioned before the proton therapy for less invasive treatment. That does not do nearly as much damage to the surrounding tissue. It is more targeted, more localised, and does not do the whole brain." Ms Roberts said she felt she and her son had been railroaded into the treatment offered by … Continue reading →